Because fluoroquinolones are the most commonly prescribed antibiotic class in the outpatient setting and reports have implicated an association between oral fluoroquinolones and an increased risk of uveitis, Sandhu and colleagues determine the hazard of uveitis with oral fluoroquinolone use in a cohort study conducted using medical claims data. A total of 843 854 individuals receiving a fluoroquinolone and 3 543 797 a β-lactam were included in the analysis. After controlling for age, race, and sex using multivariate analysis, no hazard for developing uveitis at the 30-, 60-, or 90-day observation windows was seen. Moxifloxacin produced an increased hazard for uveitis at every point. These data do not support an association between oral fluoroquinolone use and uveitis. Instead, this study showed an association between oral fluoroquinolone use and the risk for uveitis-associated systemic illnesses.